ArticleBMC rheumatology2025
Relationship between anti-Epstein-Barr virus early antigen diffuse type and restricted type immunoglobulin G antibodies and disease activity and autoantibodies in rheumatoid arthritis: a retrospective observational study.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study examined to examine the relationship of Epstein-Barr virus (EBV) in rheumatoid arthritis (RA) by evaluating disease activity and autoantibody levels in positive and negative cases using the anti-EBV early antigen diffuse type and restricted type (EA-DR) immunoglobulin G (IgG) antibody.
methodsPatients undergoing RA treatment at our hospital with anti-EBV EA-DR IgG antibodies were selected. Patient’s age, sex, RA duration, disease activity, laboratory findings, treatment details, and complications in patients with positive or negative anti-EBV EA-DR IgG antibodies were confirmed, and the relationship between RA activity, autoantibody production, and EBV was analyzed.
resultsanti-EBV EA-DR IgG antibodies were measured in 70 RA cases (30 positive and 40 negative), with a positivity rate of 43.9%. Among the positive cases, 18 underwent EBV deoxyribonucleic acid polymerase chain reaction, with 14 testing positive. Univariate analysis revealed significantly higher levels of disease activity score in 28 joints with C-reactive protein, peripheral blood lymphocyte count, anti-cyclic citrullinated peptide antibody (ACPA), and rheumatoid factor in anti-EBV EA-DR IgG antibody-positive cases. Multivariate analysis identified peripheral blood lymphocyte count and ACPA levels as significant factors.
conclusionsPatients with RA who tested positive for anti-EBV EA-Dr IgG antibodies had significantly higher ACPA than those who tested negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.